Maryland's biotechnology industry is at the forefront of scientific innovation, home to companies focusing on genetic research, drug development, and advanced therapeutic solutions. The state boasts a mix of startups and established firms, demonstrating a strong commitment to addressing global health challenges. With advances in areas like gene therapy and vaccine development, Maryland is poised for growth. Its proximity to leading research institutions fosters collaboration, paving the way for breakthrough treatments. The industry is evolving rapidly, responding to emerging diseases and the demand for personalized medicine. This underlines the importance of innovation in enhancing healthcare outcomes.

The companies highlighted here vary in size, from small teams to large organizations, reflecting Maryland's robust biotech ecosystem. Many are located in Rockville and Gaithersburg, established from 1987 to 2023. They focus on fields such as gene therapy, immunotherapy, and advanced manufacturing of biologics. Nearly all companies operate with venture capital backing, signifying investor confidence in their pioneering research and development initiatives. This snapshot provides insights into what drives growth in Maryland's biotech sector today.

Continue reading to explore Maryland's top biotechnology companies.

Top 25 Biotechnology Companies in Maryland

1. MedImmune

• Website: medimmune.com
• Ownership type: Venture Capital
• Headquarters: Gaithersburg, Maryland, United States (USA)
• Employee distribution: United States (USA) 78%, United Kingdom (UK) 18%, Other 4%
• Latest funding: $15.6B, April 2007
• Founded year: 1987
• Headcount: 1001-5000
• LinkedIn: medimmune

MedImmune, founded in 1987 and based in Gaithersburg, Maryland, is a biopharmaceutical company that operates as a subsidiary of AstraZeneca. The company is dedicated to the research and development of innovative medicines, particularly in therapeutic areas such as oncology, cardiovascular, and respiratory diseases. MedImmune's focus on improving health outcomes is evident through its extensive pipeline of products, which reflects its commitment to addressing unmet medical needs. The company employs a workforce of approximately 960 individuals, primarily located in the United States, with a significant presence in the United Kingdom. MedImmune's strategic initiatives and research efforts contribute to the broader goals of AstraZeneca, emphasizing sustainability and patient-centered care in the healthcare sector.

2. Rise Therapeutics

• Website: risetherapeutics.com
• Ownership type: Venture Capital
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), October 2024
• Founded year: 2017
• Headcount: 1-10
• LinkedIn: rise-therapeutics

Rise Therapeutics, founded in 2017 and based in Rockville, Maryland, is a biotechnology company dedicated to developing targeted immunological-based biologics. The company specializes in creating innovative oral immunotherapeutics aimed at treating chronic diseases such as autoimmunity, cancer, and infections. Rise Therapeutics leverages cutting-edge research in synthetic biology and microbiome science to drive its drug development efforts. Their proprietary Tripartite X (TPX) drug delivery platform enables the oral delivery of biologics, which is a significant advancement in the field. Recently, the company received FDA clearance for its investigational new drug (IND) application to initiate a Phase 1 clinical study for its candidate R-2487, aimed at treating rheumatoid arthritis. This highlights their active role in clinical development and their commitment to advancing novel therapies. Additionally, Rise Therapeutics has secured funding from organizations like TEDCO and the National Institutes of Health (NIH) to support their ongoing research and development initiatives.

3. American Gene Technologies International Inc.

• Website: americangene.com
• Ownership type: Venture Capital
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series D, April 2022
• Founded year: 2007
• Headcount: 11-50
• LinkedIn: american-gene-technologies-international-inc

American Gene Technologies International Inc. (AGT), founded in 2007 and based in Rockville, Maryland, is a biotechnology company that specializes in gene therapy and innovative treatments for infectious diseases, cancers, and genetic disorders. The company is particularly focused on developing clinical solutions that provide long-term cures, with significant efforts directed towards HIV and Phenylketonuria (PKU). AGT is actively conducting clinical trials and collaborating with medical researchers to advance their therapies. Their pipeline includes promising programs in immuno-oncology, where they aim to stimulate the immune system to combat solid tumors. AGT operates a 27,000 square foot facility that includes specialized laboratories for vector production and translational science, underscoring their commitment to research and development in the field of gene therapy.

4. Salubris Biotherapeutics

• Website: salubrisbio.com
• Ownership type: Corporate
• Headquarters: Gaithersburg, Maryland, United States (USA)
• Employee distribution: United States (USA) 83%, Vietnam 9%, China 9%
• Latest funding: Series A, $35.0M, April 2024
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: salubris-biotherapeutics

Salubris Biotherapeutics, Inc. is a biotechnology firm based in Gaithersburg, Maryland, established in 2016. The company is dedicated to the discovery and development of innovative biologics aimed at treating complicated diseases, with a strong focus on cardiovascular conditions and cancer. Salubris is recognized for its pioneering work in bringing bispecific antibodies into clinical trials for cardiovascular indications. Their product pipeline includes promising candidates such as JK06, a targeted antibody-drug conjugate for solid tumors, and JK07, an antibody fusion protein for heart failure. Salubris has recently raised $35 million in Series A funding, which underscores its potential and the interest it has garnered from investors. The company operates primarily in the biotechnology and pharmaceutical sectors, catering to healthcare providers and patients seeking advanced therapeutic options.

5. Innoforce Pharmaceuticals

• Website: innoforcepharma.com
• Ownership type: Venture Capital
• Headquarters: Sykesville, Maryland, United States (USA)
• Employee distribution: China 91%, United States (USA) 9%
• Latest funding: Series A, $58.8M, December 2021
• Founded year: 2018
• Headcount: 201-500
• LinkedIn: innoforcepharma

Innoforce Pharmaceuticals, founded in 2018 and based in Sykesville, Maryland, is a biotechnology company that provides contract development and manufacturing organization (CDMO) services specifically for advanced therapy medicinal products (ATMPs). The company specializes in the production of plasmid DNA, RNA, and viral vectors, which are essential components in the development of innovative therapies, including gene and cell therapies. Innoforce serves a range of clients, including biopharmaceutical companies and research institutions, ensuring the stability and efficacy of their products for both clinical and commercial applications. With a workforce of around 34 employees and a significant funding round of over $58 million in December 2021, Innoforce is positioned to play a vital role in the biotechnology sector, particularly in the rapidly evolving landscape of advanced therapies.

6. Vigene Biosciences, A Charles River Company

• Website: vigenebio.com
• Ownership type: Corporate
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $292.5M, May 2021
• Founded year: 2012
• Headcount: 51-200
• LinkedIn: vigene-biosciences

Vigene Biosciences, a Charles River Company, is based in Rockville, Maryland, and specializes in contract development and manufacturing services for the biotechnology sector. Founded in 2012, the company has carved out a niche in the production of plasmid DNA and viral vectors, which are essential components in gene and cell therapy applications. Their services support pharmaceutical and biotechnology companies throughout the drug development process, from early research to clinical trials and commercial production. With a workforce of around 30 employees, Vigene is agile and focused, allowing them to respond quickly to the evolving needs of their clients. The company has also secured substantial funding, amounting to $292.5 million, which underscores its potential for growth and innovation in the biotechnology field. As part of Charles River Laboratories, Vigene benefits from a broader network and resources, enhancing its ability to deliver high-quality solutions to its partners.

7. Integrated BioTherapeutics, Inc.

• Website: integratedbiotherapeutics.com
• Ownership type: Private
• Headquarters: Rockville, Maryland, United States (USA)
• Latest funding: $1.0M, May 2023
• Founded year: 2005
• Headcount: 11-50
• LinkedIn: integrated-biotherapeutics-inc.

Integrated BioTherapeutics, Inc. (IBT), based in Rockville, Maryland, is a biotechnology company established in 2005. The company specializes in the development of vaccines and antibody therapeutics aimed at combating infectious diseases. Their research is particularly focused on addressing emerging viral threats and antibiotic-resistant bacterial infections. IBT's pipeline includes promising candidates for the prevention and treatment of various infections, including those caused by Staphylococcus aureus, Ebola, and Marburg viruses. The company has developed a strong collaboration network with government agencies, such as the National Institute of Allergy and Infectious Diseases (NIAID), and has secured over $120 million in non-dilutive funding since its inception. Recently, IBT received $1 million in funding in May 2023, reflecting continued investor confidence in their innovative approaches to public health challenges.

8. VERALOX Therapeutics

• Website: veralox.com
• Ownership type: Venture Capital
• Headquarters: Frederick, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $24.0M, June 2023
• Founded year: 2018
• Headcount: 1-10
• LinkedIn: veralox-therapeutics

VERALOX Therapeutics, founded in 2018 and based in Frederick, Maryland, is a biotechnology firm dedicated to creating innovative therapies for life-threatening immuno-inflammatory diseases. The company is currently advancing its lead candidate, VLX-1005, which targets heparin-induced thrombocytopenia (HIT). This first-in-class small molecule inhibitor has shown promise in preclinical studies for halting immune-driven platelet activation and thrombosis. In recognition of its potential, VLX-1005 has received orphan drug designations from both the FDA and EMA, highlighting its importance in treating rare diseases. With a small team of around 18 employees, VERALOX is backed by venture capital, having raised $24 million in funding as of June 2023. This financial support underscores the company's commitment to addressing significant gaps in treatment options for patients suffering from serious conditions.

9. KamTek, Inc.

• Website: kamtekinc.com
• Ownership type: Private
• Headquarters: Frederick, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 1992
• Headcount: 11-50
• LinkedIn: kamtek-inc

KamTek, Inc., founded in 1992 and based in Frederick, Maryland, is a biotechnology company that specializes in research and development in drug development, microbiome research, and prenatal DNA testing. The company provides essential services to biotech firms and healthcare organizations, focusing on innovative solutions to combat antibiotic resistance and enhance genetic testing capabilities. KamTek is particularly noted for its work on Clostridium difficile, where it has developed patented treatments that show promise against antibiotic-resistant strains. Additionally, KamTek supports the development of prenatal DNA test kits in collaboration with Roche, utilizing advanced techniques like Next Generation Sequencing. Their facilities are equipped for a range of biotech operations, including cell biology, microbiology, and molecular biology, making them a valuable resource in the biotechnology industry.

10. Rapafusyn Pharmaceuticals

• Website: rapafusyn.com
• Ownership type: Venture Capital
• Headquarters: Baltimore, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $28.0M, June 2024
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: rapafusyn-pharmaceuticals

Rapafusyn Pharmaceuticals, founded in 2015 and based in Baltimore, Maryland, is a biotechnology firm dedicated to drug discovery and development. The company specializes in creating non-degrading molecular glues, known as RapaGlues™, which are designed to tackle difficult drug targets. Their innovative platform utilizes large DNA-encoded libraries and arrayed libraries to generate novel chemical starting points for hard-to-drug targets. This approach allows for rapid optimization of therapeutic agents, enhancing patient outcomes across various medical fields. Recently, Rapafusyn secured $28 million in Series A funding, which will support the advancement of their drug discovery platform and expand their capabilities. The company primarily serves pharmaceutical companies and research institutions, positioning itself as a key player in the biotechnology industry.

11. Early Charm

• Website: earlycharm.com
• Ownership type: Private
• Headquarters: Baltimore, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $160,000, February 2025
• Founded year: 2012
• Headcount: 51-200
• LinkedIn: early-charm-ventures-llc

Early Charm Ventures, based in Baltimore, Maryland, is a private venture studio founded in 2012. The company specializes in converting scientific discoveries into viable commercial ventures, particularly in the life sciences sector. They focus on building sustainable businesses that cater to industries such as energy, security, and advanced materials. Early Charm collaborates closely with researchers and scientists to bring innovative solutions to market, especially in drug design and biomanufacturing. Their portfolio includes companies like SilcsBio, which develops software for drug design, and Materic, a manufacturer of advanced materials. Recently, Early Charm received funding to develop a biomanufacturing incubator, further solidifying their commitment to advancing biotechnology and supporting the growth of new ventures in this field.

12. Neuraly Inc.

• Website: neuralymed.com
• Ownership type: Venture Capital
• Headquarters: Gaithersburg, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $36.0M, July 2018
• Founded year: 2016
• Headcount: 51-200
• LinkedIn: neuraly-inc

Neuraly Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, founded in 2016. The company is dedicated to developing innovative treatments for neurodegenerative diseases, with a particular focus on Parkinson's and Alzheimer's diseases. Neuraly leverages cutting-edge scientific research to create disease-modifying therapies, primarily targeting glial cell activation. Their lead product, NLY01, is a long-acting GLP-1 receptor agonist that has shown promising results in preclinical models and is currently undergoing Phase 2 clinical trials. Neuraly operates under the umbrella of D&D Pharmatech, which supports the development of revolutionary medicines through its various subsidiaries. The company has raised $36 million in funding, which underscores its commitment to advancing its pipeline and addressing the unmet medical needs in the field of neurodegeneration.

13. Immunomic Therapeutics, Inc.

• Website: immunomix.com
• Ownership type: Venture Capital
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $3.0M, April 2024
• Founded year: 2005
• Headcount: 11-50
• LinkedIn: immunomic-therapeutics-inc-

Immunomic Therapeutics, Inc. is a clinical-stage biotechnology company based in Rockville, Maryland. Founded in 2005, the company specializes in the development of immunotherapies and vaccines, primarily targeting oncology. Their proprietary technology platform, UNITE® (UNiversal Intracellular Targeted Expression), is designed to utilize the body's natural immune responses to create effective treatments for various cancers. The company is currently advancing several products through clinical trials, including ITI-1000 and ITI-1001 for glioblastoma multiforme, and ITI-3000 for Merkel cell carcinoma. These investigational therapies are being tested in collaboration with prominent research institutions, highlighting their commitment to scientific partnerships. Recently, Immunomic Therapeutics secured $3 million in funding, reflecting ongoing investor confidence in their innovative approach to cancer treatment. The company's mission is to improve patient health and extend lives through immune-based therapies, making them a relevant player in the biotechnology sector.

14. Adaptive Phage Therapeutics

• Website: aphage.com
• Ownership type: Corporate
• Headquarters: Gaithersburg, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $50.0M, March 2024
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: adaptive-phage-therapeutics

Adaptive Phage Therapeutics, based in Gaithersburg, Maryland, is a biotechnology company that focuses on the development of phage therapies to combat chronic bacterial infections. Established in 2016, the company is dedicated to creating tailored phage cocktails that target specific harmful bacteria, particularly in patients suffering from conditions like cystic fibrosis and diabetic foot osteomyelitis. Their innovative approach involves discovering and validating proprietary bacterial targets, allowing for the customization of phage compositions to effectively address these infections. The company has recently gained attention for its collaborations with major pharmaceutical partners, enhancing its therapeutic offerings. In March 2024, Adaptive Phage Therapeutics was acquired by BiomX, which underscores its strategic importance in the biotechnology sector. The company has also secured significant funding, amounting to $50 million, to support its ongoing research and development efforts.

15. Ascend Advanced Therapies

• Website: ascend-adv.com
• Ownership type: Private
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 45%, Germany 43%, United Kingdom (UK) 12%
• Latest funding: $130.6M, November 2024
• Founded year: 2022
• Headcount: 51-200
• LinkedIn: ascend-gene-cell-therapies

Ascend Advanced Therapies is a biotechnology firm based in Rockville, Maryland, established in 2022. The company specializes in the development and manufacturing of gene therapies, particularly utilizing adeno-associated viruses (AAVs). Ascend offers a range of services including AAV vector design, quality assurance, and analytical capabilities, aimed at assisting biotech and pharmaceutical companies throughout the development cycle—from pre-clinical phases to market entry. With a team of experts and a commitment to scientific innovation, Ascend is focused on delivering high-quality, scalable gene therapies. The company has recently secured over $130 million in funding, which positions it well for future growth and expansion in the competitive biotechnology landscape. Their facilities in the United States, Germany, and the United Kingdom enhance their operational capabilities and global reach, making them a valuable partner for life-science innovators.

16. Revolo Biotherapeutics

• Website: revolobio.com
• Ownership type: Venture Capital
• Headquarters: Gaithersburg, Maryland, United States (USA)
• Employee distribution: United Kingdom (UK) 62%, United States (USA) 38%
• Latest funding: Series B, $52.0M, September 2020
• Founded year: 2011
• Headcount: 11-50
• LinkedIn: immune-regulation-limited

Revolo Biotherapeutics, founded in 2011 and based in Gaithersburg, Maryland, is a biotechnology firm dedicated to developing groundbreaking therapies for autoimmune and allergic diseases. The company is actively working on two primary drug candidates: '1104, aimed at treating eosinophilic esophagitis and other allergic conditions, and '1805, which targets rheumatoid arthritis and ulcerative colitis. Both candidates are designed to reset the immune system, offering a novel approach that minimizes the side effects commonly associated with traditional treatments. Revolo has received significant venture capital funding, with its last round amounting to over $52 million in September 2020. This financial backing supports their ongoing clinical trials and research efforts, highlighting their commitment to advancing treatment options in the biotechnology field.

17. Abl

• Website: ablinc.com
• Ownership type: Corporate
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 58%, France 37%, Other 5%
• Latest funding: July 2006
• Founded year: 1961
• Headcount: 51-200
• LinkedIn: advanced-bioscience-laboratories

Abl, Inc., founded in 1961 and based in Rockville, Maryland, is a biomanufacturing company that specializes in viral vector manufacturing and immunology services. The company provides contract development and GMP manufacturing services to biotech and pharmaceutical firms, aiding them in advancing their vaccine and therapeutic candidates through preclinical and clinical development. Abl's offerings include a range of products such as ELISA kits, and they operate facilities in both the United States and Europe. With over 30 years of experience in viral vector development, Abl has produced numerous viral vectors for gene therapies, vaccines, oncolytic therapies, and immunotherapies. Their commitment to quality is evident, as their U.S. facility adheres to Good Manufacturing Practice (GMP) standards and is ISO 9001 accredited. Abl's expertise and capabilities make them a valuable partner in the biotechnology industry, particularly in the context of developing life-changing innovations.

18. Northpond Ventures

• Website: npv.vc
• Ownership type: Private
• Headquarters: Bethesda, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: northpond-ventures

Northpond Ventures is a private venture capital firm based in Bethesda, Maryland, founded in 2018. With a team of approximately 39 employees, the firm is dedicated to advancing science and technology within the biotechnology and life sciences sectors. Northpond Ventures specializes in identifying and supporting early-stage scientific research and innovation, primarily through collaborations with prestigious academic institutions such as Harvard University and MIT. Their affiliate, Northpond Labs, plays a crucial role in funding translational research and fostering an entrepreneurial culture among scientists. By providing capital and strategic guidance, Northpond Ventures helps translate scientific discoveries into viable business opportunities, thereby driving impactful research and development in the biotechnology field.

19. miRecule, Inc.

• Website: mirecule.com
• Ownership type: Venture Capital
• Headquarters: Gaithersburg, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Seed, $5.7M, May 2021
• Founded year: 2016
• Headcount: 1-10
• LinkedIn: mirecule

miRecule, Inc. is a biotechnology firm based in Gaithersburg, Maryland, founded in 2016. The company specializes in developing RNA therapeutics aimed at treating conditions such as cancer and muscular dystrophy. Utilizing their proprietary DREAmiR™ discovery platform, miRecule creates personalized therapies by analyzing genomic data from patients. This innovative approach allows them to identify genetic abnormalities and develop targeted RNA treatments. Their lead programs focus on head and neck cancer and Facioscapulohumeral Muscular Dystrophy (FSHD). miRecule has garnered attention in the industry, winning the MedCity INVEST 2024 competition and securing strategic collaborations with Sanofi to advance their therapeutic candidates. The company has also received significant funding, including a $5.7 million seed round in 2021, which supports their ongoing research and development efforts.

20. BioFactura, Inc.

• Website: biofactura.com
• Ownership type: Corporate
• Headquarters: Frederick, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $1.0M, July 2020
• Founded year: 2003
• Headcount: 11-50
• LinkedIn: biofactura-inc-

BioFactura, Inc., founded in 2003 and based in Frederick, Maryland, is a biopharmaceutical company dedicated to the development and manufacturing of high-value biosimilars and biodefense medical countermeasures. The company utilizes its proprietary StableFast™ Biomanufacturing Platform to create biosimilars, which are biologic drugs that are highly similar to already approved reference products. BioFactura is particularly focused on addressing significant health threats, including the development of therapeutics for smallpox and Marburg virus, which are classified as high-priority pathogens. Their work includes collaborations with government agencies and healthcare organizations, highlighting their role in national biodefense efforts. Recently, BioFactura has secured substantial funding, including a $16 million contract option for its smallpox therapeutic, underscoring its active participation in the biotechnology field and its commitment to advancing life-saving medicines.

21. BioServe

• Website: bioserve.com
• Ownership type: Venture Capital
• Headquarters: Beltsville, Maryland, United States (USA)
• Latest funding: January 2007
• Founded year: 1989
• Headcount: 51-200
• LinkedIn: bioserve

BioServe, known as REPROCELL, is a biotechnology firm based in Beltsville, Maryland. Founded in 1989, the company is dedicated to improving human health through innovative biomedical research. They offer a wide array of services, including stem cell research, gene editing, and clinical laboratory services. BioServe collaborates with pharmaceutical and biotechnology companies, as well as academic institutions, to facilitate drug discovery and development. Their expertise in stem cell technology and clinical applications is complemented by their commitment to regulatory compliance, ensuring that their services meet the standards set by agencies like the FDA and EMA. The company also provides access to human tissue samples and genomic services, which are critical for preclinical and clinical research. With a workforce of 51-200 employees, BioServe continues to contribute to advancements in biotechnology, particularly in the areas of precision medicine and drug discovery.

22. Deka Biosciences, Inc

• Website: dekabiosciences.com
• Ownership type: Venture Capital
• Headquarters: Germantown, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $29.9M, December 2023
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: deka-biosciences-inc

Deka Biosciences, Inc., based in Germantown, Maryland, is a biotechnology firm founded in 2018. The company specializes in developing personalized immunotherapy treatments aimed at combating cancer and inflammatory diseases. Utilizing their proprietary Diakine™ platform, Deka Biosciences creates therapies that leverage the immune system's capabilities to target specific health issues. Their approach combines anti-inflammatory and immune-stimulating cytokines, which allows for tailored treatments based on individual patient responses. The company primarily serves healthcare providers and patients seeking effective therapeutic options. Recently, Deka Biosciences secured approximately $29.9 million in funding, reflecting investor confidence in their innovative approach and potential for growth in the biotechnology sector.

23. Vector BioMed, Inc.

• Website: vectorbiomed.com
• Ownership type: Venture Capital
• Headquarters: Gaithersburg, Maryland, United States (USA)
• Employee distribution: United States (USA) 92%, India 8%
• Latest funding: $15.0M, December 2022
• Founded year: 2023
• Headcount: 11-50
• LinkedIn: vectorbiomed

Vector BioMed, Inc. is a biotechnology firm based in Gaithersburg, Maryland, that specializes in Lentiviral vector manufacturing solutions tailored for gene therapy applications. Founded in 2023, the company aims to facilitate the rapid transition from therapeutic concepts to clinical development by offering a range of services, including research grade, pre-clinical, and GMP-grade vector production. Their platform is designed to optimize vector design and manufacturing processes, ensuring high-titer outputs suitable for clinical applications. With a team that boasts extensive experience in Lentiviral vector technologies, Vector BioMed is well-equipped to support both academic institutions and biotechnology companies in their quest to develop and commercialize gene-based therapies. The company has recently raised $15 million in funding, which underscores its potential to fill a significant gap in the market for viral vector production, particularly in the context of CAR-T cell therapies and other gene therapies.

24. OriGene

• Website: origene.com
• Ownership type: Private Equity
• Headquarters: Rockville, Maryland, United States (USA)
• Employee distribution: United States (USA) 92%, China 6%, Germany 3%
• Latest funding: $17.1M, June 2015
• Founded year: 1996
• Headcount: 201-500
• LinkedIn: origene-technologies-inc

OriGene Technologies, Inc., founded in 1996 and based in Rockville, Maryland, is a biotechnology company that provides a wide array of products and services tailored for genomics and proteomics research. The company specializes in validated antibodies, cDNA clones, RNAi products, and custom research services, catering primarily to the life sciences sector. OriGene's products are designed to support researchers in their quest for scientific discovery, offering high-quality tools that enhance the efficiency and accuracy of their work. With a workforce of around 118 employees, the company has a significant presence in the United States, with additional operations in China and Germany. OriGene has also secured funding, with a reported amount of approximately $17 million in 2015, which underscores its ongoing relevance and potential for growth in the biotechnology industry.

25. Georgiamune Inc.

• Website: georgiamune.com
• Ownership type: Venture Capital
• Headquarters: Gaithersburg, Maryland, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $75.0M, August 2023
• Founded year: 2014
• Headcount: 11-50
• LinkedIn: georgiamune

Georgiamune Inc., founded in 2014 and based in Gaithersburg, Maryland, is a biopharmaceutical company dedicated to the development of innovative immunotherapeutics aimed at treating cancer and autoimmune diseases. The company specializes in reprogramming immune responses, utilizing a pipeline of first-in-class drugs designed to target significant unmet medical needs. Their portfolio includes several promising candidates, such as GIM-122, a dual-functioning antibody, and GIM-531, a Treg inhibitor, both of which are in various stages of development. Georgiamune's recent Series A funding round raised $75 million in August 2023, underscoring their potential and the interest from investors in their groundbreaking approach to immunotherapy. The company serves healthcare providers and pharmaceutical companies, positioning itself as a key player in the biotechnology sector.

Biotechnology Insights: Key Companies in Maryland

Want to Find More Biotechnology Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!